Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.
about
5-FU for genital warts in non-immunocompromised individuals5-FU for genital warts in non-immunocompromised individualsEpidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell CarcinomaEUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infectionPersistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV.Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalenceSeroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfectionRisk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.The role of sexual behavior and human papillomavirus persistence in predicting repeated infections with new human papillomavirus types.Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohortThe association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental modelsDeterminants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study.Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclassesThe impact of HPV female immunization in Italy: model based predictions.Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responsesAntigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccineThe known unknowns of HPV natural history.Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Vaccination strategies for the prevention of cervical cancer.Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodiesPrevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in menVaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirionsConcordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk populationNatural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens.Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia.Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.HPV vaccines: Translating immunogenicity into efficacy.Rapid acquisition of HPV around the time of sexual debut in adolescent girls in TanzaniaA Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected SubjectsModel for assessing human papillomavirus vaccination strategies.Projected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United KingdomReview: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme.Risk Factors for Oral Infection with Human Papillomavirus.Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases.Human papillomavirus genotype distribution in cervical samples among vaccine naïve Barbados women.HPV SEROSTATUS PRE- AND POST-VACCINATION IN A RANDOMIZED PHASE II PREPAREDNESS TRIAL AMONG YOUNG WESTERN CAPE, SOUTH AFRICAN WOMEN: THE EVRI TRIAL.
P2860
Q24235725-2BF401D0-6844-44CC-976C-5C4F9CE422A7Q24246089-7C096CAB-B4D8-4C1C-9831-99D01BBF4919Q26782499-FC232796-B559-4D54-BEA8-651612F282D2Q27010432-89366393-2247-4BA2-8A8A-F7480F990DD9Q33905022-26344A72-ED5B-4080-9BA6-84220CEC270CQ33924580-DA3700C3-5652-42FA-8851-463CD414DCA9Q33947813-E2AD72E9-EC7A-4B75-9613-7F7D62341626Q33953881-9880DB8F-7E1D-481C-9E5A-FABB21B92D91Q34059901-1F188063-6999-462C-B551-717768D40AFBQ34267472-48ABD407-CB96-41EE-ACCF-547191C9B0ECQ34366883-52DF2E4E-51BF-49A5-BB19-0FAE1DF671FDQ34583160-0D3D4C1B-E5D6-495D-B71F-2A02A31C2557Q34587057-E10A662D-6E86-44FC-990E-E2A646D2AF4FQ34994905-7246E737-F3B2-4510-9BF2-53AF9A108A41Q35117850-72927AF6-0182-4B2A-A00F-0F22B3F9105BQ35155632-98183F35-BE44-4CC4-8874-ACD3D56500D8Q35175380-F7139EEE-AEB7-4292-8438-C1D023B1B072Q35578583-EBD9B5E1-E016-4CEB-8736-F5A631AFD422Q35861286-06DE5EFF-AEE9-468E-B3CF-98EFB9E55EDBQ36066161-83AAF93F-1492-4ECD-B4E2-D4DFC5B5F34EQ36191708-915C1C6F-A8A3-4422-B88F-A6D94549BE03Q36327051-C585EEA7-2BFF-40AD-A9B5-AABAE23CBCFBQ36379269-2C84C7D0-6DF8-4720-B412-7B4D1FC5DD23Q36422554-5C12505B-881F-44FF-BD42-1DC445262F07Q36598620-2DDC45E5-A35D-478F-95C6-A354B2180CB9Q36745242-8C408FC8-2CE9-40B5-BF09-DB58EBDC565CQ36775528-9278A60C-06A6-426F-A07F-491CB34D1F65Q36794745-8B61C6A3-3573-426C-A78A-0A5E69535E6EQ36974917-4F2E257F-36C6-473F-9E9B-14B46BC34F23Q37066141-8E03DF0F-DE0E-459D-AA28-1921799DA662Q37134978-CD5DC168-F454-457B-B3DA-7EE8A4D81C28Q37219765-CAFC4F93-9EF5-4C8A-B062-8AB4966837ACQ37221868-AC292AE6-F536-46E5-9D03-760B8F8C7E65Q37302509-EBFEC700-2597-482A-9B9F-05960C275F86Q37502417-CF55716F-6F11-42E3-9AE8-815CEFFCAFCFQ38110696-4CD4FD63-2FDF-408A-9DFE-AE64A0CADC9CQ38971539-988E3BB1-B2A5-48E3-A432-8A52E1949FC5Q39202422-89282609-C0C1-451F-A8BE-4BD81FADD1B9Q40044496-BEDED126-7934-4A07-9817-57EEA0BDBAA3Q40211544-44FB6277-FB3D-4CF7-B84E-D00F427A4C32
P2860
Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Risk factors for subsequent ce ...... o HPV-16 virus-like particles.
@en
Risk factors for subsequent cervicovaginal human papillomavirus
@nl
type
label
Risk factors for subsequent ce ...... o HPV-16 virus-like particles.
@en
Risk factors for subsequent cervicovaginal human papillomavirus
@nl
prefLabel
Risk factors for subsequent ce ...... o HPV-16 virus-like particles.
@en
Risk factors for subsequent cervicovaginal human papillomavirus
@nl
P2093
P356
P1476
Risk factors for subsequent ce ...... to HPV-16 virus-like particles
@en
P2093
Gloria Y F Ho
Leah Beardsley
Michele Lempa
Robert Bierman
Robert D Burk
Yevgeniy Studentsov
P304
P356
10.1086/342972
P407
P577
2002-08-28T00:00:00Z